Skip to content
Peptigraph home

Cagrilintide Phase 2 trial (NCT03856047)

Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
706
actual
Start
1 Mar 2019 (actual)
Primary completion
2 Mar 2020 (actual)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT03856047 study arms
ArmTypeInterventionsDescription
NNC0174-0833, 4.5 mgExperimentalDrug: NNC0174-0833Patients will receive 4.5 mg of NNC0174-0833 once a week as injections for 26 weeks.
NNC0174-0833, 2.4 mgExperimentalDrug: NNC0174-0833Patients will receive 2.4 mg of NNC0174-0833 once a week as injections for 26 weeks.
NNC0174-0833, 1.2 mgExperimentalDrug: NNC0174-0833Patients will receive 1.2 mg of NNC0174-0833 once a week as injections for 26 weeks.
NNC0174-0833, 0.6 mgExperimentalDrug: NNC0174-0833Patients will receive 0.6 mg of NNC0174-0833 once a week as injections for 26 weeks.
NNC0174-0833 0.3 mgExperimentalDrug: NNC0174-0833Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
Placebo 2.4 mg (NNC0174-0833)Placebo comparatorDrug: Placebo (NNC0174-0833)Patients will receive 2.4 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
Placebo 4.5 mg (NNC0174-0833)Placebo comparatorDrug: Placebo (NNC0174-0833)Patients will receive 4.5 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
Placebo 1.2 mg (NNC0174-0833)Placebo comparatorDrug: Placebo (NNC0174-0833)Patients will receive 1.2 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
Placebo 0.6 mg (NNC0174-0833)Placebo comparatorDrug: Placebo (NNC0174-0833)Patients will receive 0.6 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
Placebo 0.3 mg (NNC0174-0833)Placebo comparatorDrug: Placebo (NNC0174-0833)Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
Liraglutide 3.0 mgActive comparatorDrug: Liraglutide 3.0 mgPatients will receive 3.0 mg of liraglutide once daily as injections for 26 weeks.
Placebo 3.0 mg (Liraglutide)Placebo comparatorDrug: Placebo (Liraglutide 3.0 mg)Patients will receive placebo 3.0 mg(liraglutide) once daily as injections for 26 weeks.
Endpoints

Primary endpoint

NCT03856047 primary outcomes
MeasureTime frame
Change in Body Weight (%)From baseline (week 0) to week 26
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT03856047 secondary outcomes
MeasureTime frame
Percentage of Participants With Weight Loss of ≥ 5% of Baseline Body Weight at 26 WeeksWeek 26
Percentage of Participants With Weight Loss of ≥ 10% of Baseline Body Weight at 26 WeeksWeek 26
Change in Body Weight (Kg)From baseline (week 0) to week 26
Change in Waist CircumferenceFrom baseline (week 0) to week 26
Change in Total CholesterolFrom baseline (week 0) to week 26
Change in High Density Lipoprotein (HDL) CholesterolFrom baseline (week 0) to week 26
Change in Low Density Lipoprotein (LDL) CholesterolFrom baseline (week 0) to week 26
Change in Very Low Density Lipoprotein (VLDL) CholesterolFrom baseline (week 0) to week 26
Change in TriglyceridesFrom baseline (week 0) to week 26
Change in Glycosylated Haemoglobin (HbA1c) (%-Point)From baseline (week 0) to week 26
Change in HbA1c (mmol/Mol)From baseline (week 0) to week 26
Change in Fasting Plasma Glucose (FPG) (mmol/L)From baseline (week 0) to week 26
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT03856047.

Dose-finding design of the cagrilintide weight-management trial

Participants were randomised 6:1 to several weekly cagrilintide levels, liraglutide 3.0 mg daily or volume-matched placebo, across a 26-week treatment period that included up to 6 weeks of escalation.[2]

The primary endpoint was the percentage change in bodyweight from baseline to week 26, analysed under two different estimands.[2]

Weight and tolerability results reported for cagrilintide

On the trial-product estimand, mean weight reductions with cagrilintide 0.3-4.5 mg ranged from 6.0% to 10.8%, against 3.0% with placebo.[2]

Cagrilintide 4.5 mg produced a larger reduction than liraglutide 3.0 mg (10.8% against 9.0%, p=0.03).[2]

Permanent discontinuation occurred in 73 participants (10%), mostly because of adverse events (30 participants, 4%).[2]

Gastrointestinal adverse events affected 41%-63% of cagrilintide recipients against 32% on placebo, with nausea at 20%-47% against 18%.[2]

Sources

  1. 1Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026

Found an error? Report a correction.